NovaBridge Biosciences Announces Positive Phase 2a Results for VIS-101 in Wet AMD, Citing Potential Best-in-Class Durability

summarizeSummary

NovaBridge Biosciences announced positive topline Phase 2a results for its lead ophthalmology candidate, VIS-101, in wet AMD, highlighting strong efficacy, durability, and a favorable safety profile.

check_boxKey Events

• Positive Phase 2a Topline Results for VIS-101

  NovaBridge Biosciences and its subsidiary Visara, Inc. announced positive topline results from the Phase 2a study of VIS-101, a dual VEGF-A X ANG-2 inhibitor for retinal vascular diseases, specifically wet age-related macular degeneration (wet AMD).

• Strong Efficacy and Durability Demonstrated

  VIS-101 produced rapid, robust, and durable treatment responses, with mean improvement in BCVA of >10 ETDRS letters and median CST reduction of 100-150 µm. Approximately two-thirds of patients were retreatment-free at 4 months, and about half at 6 months, suggesting potential best-in-class durability.

• Favorable Safety Profile

  The study reported a favorable safety profile with no dose-limiting toxicity, and only two patients experiencing treatment-related adverse events in the 6mg dose group.

• Advancement to Later Stages Planned

  Following these results, a Phase 2b dose-determining study is expected to begin in H2 2026, with a global Phase 3 program anticipated to commence in 2027.

auto_awesomeAnalysis

NovaBridge Biosciences reported highly encouraging topline Phase 2a data for VIS-101 in wet AMD, a significant de-risking event for the company's lead ophthalmology asset. The drug demonstrated rapid, robust, and durable treatment responses, with key metrics like BCVA improvement and CST reduction showing strong efficacy. Critically, the data suggests potential best-in-class durability, with a high percentage of patients remaining retreatment-free for extended periods, which could be a major competitive advantage in the large wet AMD market. The favorable safety profile further strengthens the drug's potential. This positive clinical milestone provides a strong foundation for advancing VIS-101 into Phase 2b and global Phase 3 studies, significantly enhancing the company's value proposition and pipeline visibility.